MDxHealth SA

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, The Netherlands, Belgium, Spain, Poland, Italy, Rest of EU, and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MDxHealth reports strong Q2 revenue growth and operational improvements

MDxHealth's Q2 2024 performance reflects robust revenue growth, driven by increased test volumes and improved margins.
The company's strategic focus on revenue drivers and operational efficiency has led to a reduction in operating losses.
While facing challenges in a competitive market, MDxHealth is well-positioned to capitalize on growth opportunities and deliver strong results.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, Europe and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

MDxHealth SA (NASDAQ:MDXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Michael K. McGarrity - Chief Executive Officer and Director Ron Kalfus - Chief Financial Officer Conference Call Participants Vidyun Bais - BTIG Thomas Flaten - Lake Street Capital Markets Jason Bednar - Piper Sandler Operator Good day, and welcome to the MDxHealth Third Quarter 2024 Earnings Call.

MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript

Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K.

MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024

MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“Ordinary Shares”) in a registered public offering (the “Offering”) at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducting commissions and estimated offering expenses. A strategic partner is purchasing 1,500,000 Ordinary Shares in this Offering directly from the Company rather than through the underwriters.

MDxHealth Announces Pricing of Offering of Ordinary Shares

MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40.0 million of ordinary shares of the Company without nominal value ("Ordinary Shares") in a registered public offering (the “Offering”). The Company also expects to grant the underwriters a 30-day option to purchase up to 15% of the Ordinary Shares being offered, excluding any Ordinary Shares purchased directly from the Company in the Offering pursuant to any separate Securities Purchase Agreement.

MDxHealth Announces Launch of Offering of Ordinary Shares

MDxHealth SA (NASDAQ:MDXH ) Q2 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Vidyun Bais - BTIG Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Operator Greetings, and welcome to the MDxHealth Second Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this call is being recorded.

MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript

MDxHealth (NASDAQ: MDXH ) just reported results for the second quarter of 2024. MDxHealth reported earnings per share of -42 cents.

MDXH Stock Earnings: MDxHealth Misses EPS, Beats Revenue for Q2 2024

MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 million Year-over-year H1 revenues increase by 34% to 42.0 million Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the second quarter and half year ended June 30, 2024. Michael K.

MDxHealth Reports Q2 and Half Year 2024 Results

MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and six-month period ended June 30, 2024, after market close on Wednesday, August 21, 2024. Title: MDxHealth Presents Second Quarter and First Half 2024 Financial Results and Corporate Update Conference Call and Webcast Speakers: Michael K.

MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21

MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary Q2 and half year 2024 revenues and cash. The Company expects to report Q2 and half year 2024 revenues of approximately $22.2 and $42.0 million, respectively, representing year-over-year growth of 32% and 34%, respectively, and representing sequential growth from Q1 of 12%.

MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance

Mdxhealth Appoints Sanford J. Siegel, M.D.

Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024.

Mdxhealth to Present at Upcoming Investor Conferences

MDxHealth SA (NASDAQ:MDXH ) Q1 2024 Results Conference Call May 1, 2024 8:30 AM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Jason Bednar - Piper Sandler Mark Massaro - BTIG Daniel Brennan - TD Cowen Thomas Vranken - KBC Operator Good morning, ladies and gentlemen, and welcome to the MDxHealth First Quarter 2024 Earnings Call. At this time, all lines are in a listen-only mode.

MDxHealth SA (MDXH) Q1 2024 Earnings Call Transcript

MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 million Increasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2024 and the closing of a new debt facility with OrbiMed. Michael K.

MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient's risk of developing cancer, disease progression, and response to prostate cancer therapies.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

MDxHealth SA (NASDAQ:MDXH ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Mark Massaro - BTIG Operator Good afternoon, ladies and gentlemen and welcome to the MDxHealth Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode.

MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Michael K.

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6

Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024.

Mdxhealth Announces Resignation of Board Member

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary fourth quarter and full year 2023 revenues and issued 2024 revenue guidance. The Company expects to report fourth quarter and full year 2023 revenues of approximately $19.4 and $70.2 million, respectively, with a year-end cash balance of $22.4 million, which reflects $2.3 million of non-operating and non-recurring cash use in the fourth quarter, primarily attributed to the transition to a sole listing on NASDAQ.

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance

NEWS RELEASE – REGULATED INFORMATION DECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET              MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – December 18, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces the completion of its transition to a single listing on Nasdaq. In accordance with prior announcements made by the Company and the corporate event notice issued by Euronext on December 6, 2023, the last trading day of the Company's ordinary shares (the "Shares") on the regulated market of Euronext Brussels was December 15, 2023.

MDxHealth Announces Completion of Transition to Single Listing on Nasdaq

NEWS RELEASE – REGULATED INFORMATION NOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – November 27, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces the completion of the mandatory exchange under the Company's American Depositary Shares ("ADSs") facility (the "Mandatory ADS Exchange"), the start of the transition to a single listing on Nasdaq, and details on the process for repositioning of the Company's shares from the Euronext Brussels trading system to the Nasdaq trading system. Mandatory ADS Exchange and transition to single listing on Nasdaq The Company announced on October 2, 2023, that its board of directors had determined that it is in the best interest of the Company, its investors and other stakeholders to consolidate all trading of the Company's securities on one exchange in the United States.

MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq

NEWS RELEASE November 14, 2023, 4PM ET/ 22:00 CET MDxHealth to Participate in the 35 th Annual Piper Sandler Healthcare Conference IRVINE, CA, and HERSTAL, BELGIUM – November 14, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in a fireside chat at the 35th Piper Sandler Healthcare Conference on Wednesday, November 29, 2023, at 9:00am ET.

MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference

MDxHealth SA (OTC:MXDHF) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Daniel Sammarco - TD Cowen Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Operator Good afternoon, ladies and gentlemen, and welcome to the MDxHealth Third Quarter 2023 Earnings Call. Before we begin, I would like to remind everyone that we will make forward-looking statements during today's call, whether in prepared remarks or during the Q&A session.

MDxHealth SA (MXDHF) Q3 2023 Earnings Call Transcript

NEWS RELEASE – REGULATED INFORMATION 8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET             MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 IRVINE, CA, and HERSTAL, BELGIUM – November 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2023. Michael K.

MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023

NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION NOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET

MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation

News for MDxHealth SA Stock (MDXH)